Image source: Shutterstock

Highlights

  • AMS reported FY24 revenue growth of 40.6% year-on-year, reaching GBP 177.5 million
  • Adjusted profit before tax rose 13.5% yoy to GBP 29.4 million
  • The successful integration of Peters Surgical and Syntacoll expanded AMS’s product range and global footprint
  • A full-year dividend of 2.60 pence per share was proposed, up 10.2% from the prior year

Advanced Medical Solutions Group PLC (LSE:AMS), a constituent of the FTSE AIM UK 50 Index, is an independent UK-based company focused on developing and manufacturing tissue-healing technologies designed to improve patient outcomes.

The integration of Peters Surgical and Syntacoll in the financial year 2024 (FY24) has broadened the company’s product portfolio, geographical reach and delivered a 43% increase in revenue at constant currency.

FY24 Financial Metrics

In FY24, Advanced Medical Solutions reported a revenue of GBP 177.5 million, marking a 40.6% year-on-year increase from GBP 126.2 million in FY23. This growth was primarily driven by the performance of US LiquiBand, expansion in other key surgical product categories, and the strategic acquisitions of Peters Surgical and Syntacoll.

Adjusted profit before tax rose by 13.5% YoY to GBP29.4 million in FY24, up from GBP25.9 million the previous year, reflecting the impact of acquisition and integration-related costs.

The company has proposed a full-year dividend of 2.60 pence per share, representing a 10.2% YoY increase, with a final dividend of 1.83 pence per share scheduled for payment on 20 June 2025, and an ex-dividend date of 29 May 2025.

Company Outlook

The company states that the acquisition of Peters Surgical has significantly expanded AMS’ global footprint and product capabilities. With this integration progressing well and further synergies expected over the next three years, the enlarged group is expected to enhance both operational efficiency and profit margins. Additionally, the early success of LIQUIFI in the US, following key GPO approvals, sets the stage for accelerated sales growth in 2025.

Top 10 Shareholders

The top 10 shareholders of AMS together account for approximately 45.15% of the total shares outstanding. Octopus Investments Limited holds the largest stake at around 12.00%, followed by Rathbone Unit Trust Management Limited with approximately 8.59%, as illustrated in the chart below.

Stock Information

The stock has risen approximately 8.31% over the past month but is down about 7.30% over the last six months. It has a 52-week range between GBX 168.40 and GBX 275.83 and is currently trading below the average of this range, closing at GBX 192.8 as of 09 May 2025.

Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference data for all price data, currency, technical indicators, support, and resistance levels is 09 May 2025. The reference data in this report has been partly sourced from EODHD/Others.

 Technical Indicators Defined

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.